{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:17:37Z","timestamp":1787584657571,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Aplastic anemia (AA) is a life-threatening bone marrow failure syndrome. The advent of next-generation sequencing (NGS) has shed light on the link between somatic mutations (SM) and the efficacy of immunosuppressive therapy (IST) in AA patients. However, the relationship between SM and hematopoietic stem cell transplantation (HSCT) has not been extensively explored. In this retrospective analysis, we examined 166 AA patients who received HSCT or IST at our institution between May 2019 and December 2023. NGS was conducted on 66 genes within bone marrow cells to investigate the correlation between SM and the prognosis and therapeutic response in AA patients, as well as to assess the impact of mutation types on HSCT outcomes. Clinical data were gathered from 166 AA patients, comprising 84 males and 82 females, with a median age of 32 years (ranging from 9 to 75 years). In our study, a total of 151 somatic mutations were identified across 84 patients (50.6%), with 42 patients (25.3%) presenting a single mutation and 26 patients (15.7%) harboring two mutations. The top five genes with the highest mutation frequency were BCOR\/BCORL1 (12.6%), ASXL1 (8.6%), TET2 (6.6%), CEBPA (5.3%), and GATA2 (4.6%). We stratified patients into SM and No-SM groups based on the presence of mutations and further divided them into HSCT and IST groups to assess the influence of mutation types on treatment response and survival within and between these groups. The findings were as follows: 1.Patients in the HSCT group exhibited a higher treatment response (OR 85.9% vs. 68.4%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), although there was no significant difference in survival. 2.Patients with favorable mutations, such as PIGA and BCOR\/BCORL1, experienced significantly improved response and survival compared to those with unfavorable mutations like ASXL1, DNMT3A, and TET2 (OR 93.7% vs. 72%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) (3-year OS 93.7% vs. 80%, <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). 3.The HSCT-Favorable group demonstrated superior response rates (OR 100% vs. 67.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and longer survival (3-year OS 100% vs. 67.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) compared to the IST-Favorable group. This study underscores that AA patients carrying favorable mutations, particularly BCOR\/BCORL1, tend to have a more robust response and better prognosis than those without mutations or those with unfavorable mutations, such as ASXL1\/DNMT3A. These findings are especially pertinent to HSCT, highlighting the importance of NGS prior to initiating treatment.<\/jats:p>","DOI":"10.1007\/s00277-024-06152-6","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:53:17Z","timestamp":1738043597000},"page":"1877-1886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hematopoietic stem cell transplantation and immunosuppressive therapy: implications of clonal haematopoiesis"],"prefix":"10.1007","volume":"104","author":[{"given":"Zhengwei","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"12","key":"6152_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-017-0511-z","volume":"18","author":"SA Peslak","year":"2017","unstructured":"Peslak SA, Olson T, Babushok DV (2017) Diagnosis and treatment of aplastic Anemia. Curr Treat Options Oncol 18(12):70","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"6152_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/pbc.24875","volume":"61","author":"DA Williams","year":"2014","unstructured":"Williams DA, Bennett C, Bertuch A, Bessler M, Coates T, Corey S et al (2014) Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC). Pediatr Blood Cancer 61(5):869\u2013874","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"6152_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjh.17403","volume":"194","author":"P Scheinberg","year":"2021","unstructured":"Scheinberg P (2021) Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries. Br J Haematol 194(6):954\u2013969","journal-title":"Br J Haematol"},{"issue":"3","key":"6152_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12185-020-02955-1","volume":"112","author":"L Ye","year":"2020","unstructured":"Ye L, Zhang F, Kojima S (2020) Current insights into the treatments of severe aplastic anemia in China. Int J Hematol 112(3):292\u2013299","journal-title":"Int J Hematol"},{"issue":"1","key":"6152_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12865-020-0340-x","volume":"21","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F (2020) Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis. BMC Immunol 21(1):10","journal-title":"BMC Immunol"},{"issue":"2","key":"6152_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172(2):187\u2013207","journal-title":"Br J Haematol"},{"issue":"1","key":"6152_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1414799","volume":"373","author":"T Yoshizato","year":"2015","unstructured":"Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D et al (2015) Somatic mutations and Clonal Hematopoiesis in aplastic Anemia. N Engl J Med 373(1):35\u201347","journal-title":"N Engl J Med"},{"issue":"17","key":"6152_CR8","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","volume":"124","author":"AG Kulasekararaj","year":"2014","unstructured":"Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S et al (2014) Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 124(17):2698\u20132704","journal-title":"Blood"},{"issue":"4","key":"6152_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/bjh.14691","volume":"178","author":"HS Park","year":"2017","unstructured":"Park HS, Park SN, Im K, Kim SM, Kim JA, Hwang SM et al (2017) Telomere length and somatic mutations in correlation with response to immunosuppressive treatment in aplastic anaemia. Br J Haematol 178(4):603\u2013615","journal-title":"Br J Haematol"},{"issue":"26","key":"6152_CR10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG et al (2014) Age-related clonal hematopoiesis Associated with adverse outcomes. N Engl J Med 371(26):2488\u20132498","journal-title":"N Engl J Med"},{"issue":"6327","key":"6152_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R et al (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355(6327):842\u2013847","journal-title":"Science"},{"issue":"2","key":"6152_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E et al (2017) Clonal hematopoiesis and risk of atherosclerotic Cardiovascular Disease. N Engl J Med 377(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"3","key":"6152_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3324\/haematol.13829","volume":"94","author":"P Scheinberg","year":"2009","unstructured":"Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM et al (2009) Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 94(3):348\u2013354","journal-title":"Haematologica"},{"key":"6152_CR14","doi-asserted-by":"crossref","unstructured":"Jaiswal S (2020) Clonal hematopoiesis and non-hematologic disorders. Blood. blood.2019000989.","DOI":"10.1182\/blood.2019000989"},{"issue":"1","key":"6152_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP et al (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126(1):9\u201316","journal-title":"Blood"},{"key":"6152_CR16","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.blre.2020.100772","volume":"47","author":"R Iftikhar","year":"2021","unstructured":"Iftikhar R, Chaudhry QUN, Anwer F, Neupane K, Rafae A, Mahmood SK et al (2021) Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev 47:100772","journal-title":"Blood Rev"},{"issue":"1","key":"6152_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1200\/JCO.22.00710","volume":"41","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L et al (2023) Clinical and molecular determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. JCO 41(1):132\u2013142","journal-title":"JCO"},{"issue":"24","key":"6152_CR18","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1182\/blood.2021010958","volume":"138","author":"P Sportoletti","year":"2021","unstructured":"Sportoletti P, Sorcini D, Falini B (2021) BCOR gene alterations in hematologic diseases. Blood 138(24):2455\u20132468","journal-title":"Blood"},{"issue":"48","key":"6152_CR19","doi-asserted-by":"publisher","first-page":"41479","DOI":"10.1074\/jbc.M111.284687","volume":"286","author":"C Holz-Schietinger","year":"2011","unstructured":"Holz-Schietinger C, Matje DM, Harrison MF, Reich NO (2011) Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation. J Biol Chem 286(48):41479\u201341488","journal-title":"J Biol Chem"},{"issue":"13","key":"6152_CR20","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","volume":"76","author":"S Asada","year":"2019","unstructured":"Asada S, Fujino T, Goyama S, Kitamura T (2019) The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci 76(13):2511\u20132523","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"6152_CR21","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.3324\/haematol.2014.120931","volume":"100","author":"J Huang","year":"2015","unstructured":"Huang J, Ge M, Lu S, Shi J, Li X, Zhang J et al (2015) Mutations of ASXL1 and TET2 in aplastic anemia. Haematologica 100(5):e172\u2013e175","journal-title":"Haematologica"},{"issue":"2","key":"6152_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjh.13317","volume":"169","author":"M Collin","year":"2015","unstructured":"Collin M, Dickinson R, Bigley V (2015) Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol 169(2):173\u2013187","journal-title":"Br J Haematol"},{"issue":"15","key":"6152_CR23","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood-2016-09-687889","volume":"129","author":"JD Crispino","year":"2017","unstructured":"Crispino JD, Horwitz MS (2017) GATA factor mutations in hematologic disease. Blood 129(15):2103\u20132110","journal-title":"Blood"},{"issue":"4","key":"6152_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.hoc.2018.04.004","volume":"32","author":"LJ McReynolds","year":"2018","unstructured":"McReynolds LJ, Calvo KR, Holland SM (2018) Germline GATA2 mutation and bone marrow failure. Hematol Oncol Clin North Am 32(4):713\u2013728","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"6152_CR25","doi-asserted-by":"publisher","first-page":"eabl5220","DOI":"10.1126\/sciadv.abl5220","volume":"8","author":"X Chen","year":"2022","unstructured":"Chen X, Zhou W, Song RH, Liu S, Wang S, Chen Y et al (2022) Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity. Sci Adv 8(4):eabl5220","journal-title":"Sci Adv"},{"issue":"1","key":"6152_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","volume":"6","author":"S Wakita","year":"2022","unstructured":"Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y et al (2022) Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv 6(1):238\u2013247","journal-title":"Blood Adv"},{"key":"6152_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/HS9.0000000000000212","volume":"3","author":"HJ Wood","year":"2019","unstructured":"Wood HJ, Marsh JCW (2019) Somatic mutations in aplastic anemia: significance for classification, therapy, and outcome. HemaSphere 3:10\u201312","journal-title":"HemaSphere"},{"issue":"5","key":"6152_CR28","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41375-021-01231-3","volume":"35","author":"S Lundgren","year":"2021","unstructured":"Lundgren S, Ker\u00e4nen MAI, Kankainen M, Huuhtanen J, Walldin G, Kerr CM et al (2021) Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. Leukemia 35(5):1365\u20131379","journal-title":"Leukemia"},{"issue":"1","key":"6152_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/asheducation-2018.1.457","volume":"2018","author":"DV Babushok","year":"2018","unstructured":"Babushok DV (2018) A brief, but comprehensive, guide to clonal evolution in aplastic anemia. Hematol Am Soc Hematol Educ Program 2018(1):457\u2013466","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"17","key":"6152_CR30","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2017-02-767731","volume":"130","author":"E Negoro","year":"2017","unstructured":"Negoro E, Nagata Y, Clemente MJ, Hosono N, Shen W, Nazha A et al (2017) Origins of myelodysplastic syndromes after aplastic anemia. Blood 130(17):1953\u20131957","journal-title":"Blood"},{"issue":"10","key":"6152_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ajh.25592","volume":"94","author":"G Zheng","year":"2019","unstructured":"Zheng G, Chen P, Pallavajjalla A, Haley L, Gondek L, Dezern A et al (2019) The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. Am J Hematol 94(10):1141\u20131148","journal-title":"Am J Hematol"},{"issue":"9","key":"6152_CR32","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1038\/s41375-022-01636-8","volume":"36","author":"EM Groarke","year":"2022","unstructured":"Groarke EM, Patel BA, Shalhoub R, Gutierrez-Rodrigues F, Desai P, Leuva H et al (2022) Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia. Leukemia 36(9):2328\u20132337","journal-title":"Leukemia"},{"issue":"4","key":"6152_CR33","doi-asserted-by":"publisher","first-page":"a035675","DOI":"10.1101\/cshperspect.a035675","volume":"10","author":"J Kaner","year":"2020","unstructured":"Kaner J, Desai P, Mencia-Trinchant N, Guzman ML, Roboz GJ, Hassane DC (2020) Clonal hematopoiesis and Premalignant diseases. Cold Spring Harb Perspect Med 10(4):a035675","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"6152_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S et al (2018) Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med 24(7):1015\u20131023","journal-title":"Nat Med"},{"issue":"7714","key":"6152_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E et al (2018) Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559(7714):400\u2013404","journal-title":"Nature"},{"issue":"8","key":"6152_CR36","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1007\/s10238-023-01067-4","volume":"23","author":"L Liu","year":"2023","unstructured":"Liu L, Zhang D, Fu Q, Wang J, Yu J, Chen D et al (2023) Clinical implications of myeloid malignancy\u2013related somatic mutations in aplastic anemia. Clin Exp Med 23(8):4473\u20134482","journal-title":"Clin Exp Med"},{"issue":"8","key":"6152_CR37","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/blood.2022016508","volume":"140","author":"LJ McReynolds","year":"2022","unstructured":"McReynolds LJ, Rafati M, Wang Y, Ballew BJ, Kim J, Williams VV et al (2022) Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. Blood 140(8):909\u2013921","journal-title":"Blood"},{"issue":"3","key":"6152_CR38","first-page":"491","volume":"44","author":"ML Zhang","year":"2022","unstructured":"Zhang ML, Chen WS, Han B (2022) [Somatic mutations of acquired aplastic Anemia]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 44(3):491\u2013496","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06152-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06152-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:11:08Z","timestamp":1745575868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06152-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6152"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06152-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocol was established according to the ethical guidelines of the Helsinki Declaration and was approved by the Ethics Committee of The First Affiliated Hospital of Zhejiang Chinese Medical University. (approval number: 2024-KLS-290-01). Written informed consent was obtained from individual or guardian participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}